Navigation Links
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

pendent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPMTM are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

SOURCE Soligenix, Inc.

RELATED LINKS
http://www.soligenix.com

'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Reports Third Quarter 2009 Financial Results
2. Soligenix to Present at 8th Annual BIO Investor Forum
3. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
4. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
5. Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
6. ERT to Present at the UBS 20th Annual Global Healthcare Services Conference on February 8, 2010
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NeurogesX to Present at J.P. Morgan Health Care Conference
11. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 Immunomic Therapeutics, Inc. announced today ... grant to support the continued preclinical development of a ... approximately $255,000 over one year to conduct vaccine validation ... allergy, affect over one million Americans and are the ... nut exposure is also a risk for peanut allergics, ...
(Date:9/17/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, today announced that its ... the United States on the OTCQX ... 17, 2014 on the OTCQX under the symbol SQIDF.  ... Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... Escape Alert, LLC . filed international patents for an ... their pet has escaped and enable them to track their pet’s ... body. This is the first implantable microchip with GPS. , ... many years, they are passive until read by scanners, do not ... or alert the owner that the pet has escaped. Escape ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5
... NEW YORK, July 24 American Oriental,Bioengineering, Inc. (NYSE: ... release,second quarter 2008 financial results on Monday, August 11, ... a conference call at 5:00 pm ET on August ... Listeners may,access the call by dialing 1-800-599-9816 or 1-617-847-8705 ...
... SOUTH SAN FRANCISCO, Calif., July 24 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that it will hold ... results and provide a corporate update,including an update ... lead product candidate. Jerry McMahon, Ph.D., chairman and ...
... July 24 Sagent Pharmaceuticals, Inc.,a privately-held specialty ... for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. Sagent ... vials and 6g pharmacy bulk package vials. According ... the United States were,approximately $45.7 million., "Sagent ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
(Date:9/17/2014)... bags and their environmental impact recently scored a major ... ban on the bags, and Governor Jerry Brown is ... is not yielding without a fight, according to an ... weekly newsmagazine of the American Chemical Society. , Alexander ... anti-bag campaign logged its first small victory in 1990 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... treatment for stroke has taken a major step forward following ... The University of Manchester have shown in laboratory studies that ... injury and death. , The team, led by Professor Nancy ... of the first small trial of IL-1ra in patients, which ...
... of diseases , A team of international researchers ... 15 regulates inflammation, a finding with implications for ... disease, diabetes, obesity, Alzheimer's, and infections. The ... issue of Nature Genetics. , Investigators believe this ...
... Hopkins researcher, with colleagues in Sweden and at the ... view of cancer as a group of diseases with ... alterations within a cell's nuclear DNA may have to ... January issue of Nature Reviews Genetics, available online Dec. ...
Cached Biology News:Stroke treatment a step closer after trial 2Scientists pinpoint inflammation gene 2Scientists pinpoint inflammation gene 3Scientists pinpoint inflammation gene 4New view of cancer: 'Epigenetic' changes come before mutations 2
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... dual parameter assay for mitochondrial membrane ... Active caspases are detected by carboxyfluorescein ... are cell-permeable, non-cytotoxic and bind covalently ... cells. At the same time the ...
... Mouse P815 cells were cultured in DMEM ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
Biology Products: